Eli Lilly Obesity Drug

Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.

Fast Company · 13d

Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.

Fox News · 9h

Diabetes and weight loss drugs shown to reduce alcohol-related hospitalizations, study finds

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.

MarketWatch · 4d

Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.

Verywell Health on MSN · 3d

Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.

21h

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

BioPharma Dive4d

Metsera raises $215M to accelerate obesity drug plans

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

NJBIZ2h

Pharma giants defend against high-stakes lawsuit over weight loss drugs

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

20h

Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Yahoo Finance2d

Eli Lilly and Company (LLY)

One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic. Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such ...

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

19h

The UK thinks weight loss drugs could ease unemployment. Experts say that’s a fantasy

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Why Eli Lilly’s CEO says failing faster is essential to the company’s success

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results